J. Goldman & CO LP Bio Atla, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 85,500 shares of BCAB stock, worth $58,994. This represents 0.09% of its overall portfolio holdings.
Number of Shares
85,500Holding current value
$58,994% of portfolio
0.09%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
65Shares Held
17.4MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$1.84 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$1.74 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$1.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$1.28 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$603,1120.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $25M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...